[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654239":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":23,"studyPopulation":26,"armGroups":27,"interventions":23,"overallOfficials":37,"centralContacts":41,"locations":51,"responsibleParty":69,"collaborators":71,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":23,"enrollmentInfo":90,"targetDuration":23,"studyType":93,"phases":23,"briefSummary":94,"conditions":95,"keywords":111,"overallStatus":53,"whyStopped":23,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"To contribute to and continue to sustain a repository biological samples and data from individuals with age-related neurodegenerative conditions.","To contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and\u002For RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions.","This is a natural history study-participants are followed from date of enrollment until death, withdraw, or funding is no longer available, or until 600 months have passed.",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"To collect and bank data and biospecimen samples","To collect and bank data and biospecimen samples locally and at collaborating data and biobank repositories in support of neurodegenerative disease research. Data and biospecimen samples may be collected as part of an external protocol (e.g., a different Penn IRB-approved observational protocol, clinical trial, or consortium study) in which participants may be co-enrolled",{"measure":18,"description":19,"timeFrame":12},"To collect data and biospecimen samples from people who wish to participate in research but are unable to participate or do not meet eligibility criteria for other research protocols at our lab.","To collect data and biospecimen samples from people who wish to participate in research but are unable to participate or do not meet eligibility criteria for other research protocols at our lab, e.g., a carrier of a rare genetic variant associated with a neurodegenerative disease.",{"measure":21,"description":22,"timeFrame":12},"To extend analysis, maintenance, and sharing of existing data.","To extend analysis, maintenance, and sharing of existing data, imaging, and biospecimen samples collected by our lab under previous research protocols",null,{"allocation":23,"interventionModel":23,"interventionModelDescription":23,"primaryPurpose":23,"observationalModel":25,"timePerspective":6,"maskingInfo":23},"COHORT","This study will recruit adults over the age of 18 who fit into one of the three study groups defined in the eligibility criteria above.",[28,31,34],{"label":29,"type":23,"description":30,"interventionNames":23},"People with a clinical diagnosis of neurodegenerative disease","People with a clinical diagnosis of a neurodegenerative disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), primary progressive aphasia (PPA), limbic-predominant age-related TDP-43 encephalopathy (LATE), corticobasal syndrome (CBS), posterior cortical atrophy (PCA), primary lateral sclerosis (PLS), primary muscular atrophy (PMA), or individuals with a suspected neurodegenerative dementia and\u002For movement disorder of unknown etiology will be considered for enrollment.",{"label":32,"type":23,"description":33,"interventionNames":23},"Family members of individuals meeting criteria for group 1","Family Members of individuals who meet the criteria of group 1, who are people who may or may not be at risk for a similar neurodegenerative disease, who may or may not be symptomatic, and who may or may not have known or unknown genetic risk.",{"label":35,"type":23,"description":36,"interventionNames":23},"Healthy Controls","People with no known neurological disease who will provide control data.",[38],{"name":39,"affiliation":5,"role":40},"Corey McMillan, PhD","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":23,"email":46},"Cara Joyce, MPH","CONTACT","267-271-0740","cara.joyce@pennmedicine.upenn.edu",{"name":48,"role":44,"phone":49,"phoneExt":23,"email":50},"Emily Xie","16109553114","emily.xie@pennmedicine.upenn.edu",[52],{"facility":5,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-75.16362,39.95238,{"lat":63,"lon":62},[66,67,68],{"name":43,"role":44,"phone":45,"phoneExt":23,"email":46},{"name":48,"role":44,"phone":23,"phoneExt":23,"email":50},{"name":39,"role":40,"phone":23,"phoneExt":23,"email":23},{"type":40,"investigatorFullName":39,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Associate Professor of Neurology",[72,74,77],{"name":73,"class":6},"University of Pennsylvania Institute on Aging",{"name":75,"class":76},"National Institute on Aging (NIA)","NIH",{"name":78,"class":76},"National Institute of Neurological Disorders and Stroke (NINDS)","100654239","biofluid-research-on-age-related-or-inherited-neurodegeneration-100654239",false,"NCT07798700","Biofluid Research on Age-Related or Inherited Neurodegeneration","Biofluid Research on Age-Related or Inherited Neurodegeneration (BRAIN)","BRAIN","Inclusion Criteria:\n\n1. People with a clinical diagnosis of a neurodegenerative disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), primary progressive aphasia (PPA), limbic-predominant age-related TDP-43 encephalopathy (LATE), corticobasal syndrome (CBS), posterior cortical atrophy (PCA), primary lateral sclerosis (PLS), primary muscular atrophy (PMA), or individuals with a suspected neurodegenerative dementia and\u002For movement disorder of unknown etiology will be considered for enrollment\n2. Family Members of individuals who meet the criteria of group 1, who are people who may or may not be at risk for a similar neurodegenerative disease, who may or may not be symptomatic, and who may or may not have known or unknown genetic risk.\n3. People with no known neurological disease who will provide control data.\n\nExclusion Criteria:\n\n1. Anyone who is under the age of 18.\n2. Anyone with a condition or in a situation which, in the investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological, and other medical conditions (such as cardiac, neurosurgical, infectious conditions).",true,"ALL","18 Years",{"count":91,"type":92},1000,"ESTIMATED","OBSERVATIONAL","The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and\u002For RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the molecular and genetic basis of these diseases and their risk factors.",[96,97,98,99,100,101,102,103,104,105,106,107,108,109,110],"Frontotemporal Degeneration (FTD)","ALS (Amyotrophic Lateral Sclerosis)","Primary Progressive Aphasia (PPA)","Familial Frontotemporal Lobar Degeneration (fFTLD)","Fronto-temporal Lobar Dementia","Dementia With Lewy Bodies (DLB)","Cortical Basal Syndrome (CBS)","Alzheimer's Disease (AD)","Progressive Supranuclear Palsy(PSP)","Parkinson's Disease (PD)","Parkinson's Disease Dementia (PDD)","Limbic-predominant Age-related TDP-43 Encephalopathy (LATE)","Posterior Cortical Atrophy (PCA)","Primary Lateral Sclerosis (PLS)","Primary Muscular Atrophy (PMA)",[112,113,114,115,116,117,118,119,120],"Dementia","ALS","FTD","Familial FTD","Familial ALS","Neurodegeneration","Neuromuscular Diseases","Movement Disorder","Neurodegenerative Diseases","2026-08-28",{"date":123,"type":124},"2026-09-01","ACTUAL",{"date":126,"type":124},"2025-12-12",{"date":128,"type":92},"2070-01-01",{"name":5,"class":6},1]